US Bancorp DE Grows Stock Holdings in QIAGEN N.V. $QGEN

Key Points

• US Bancorp DE increased its holdings in QIAGEN N.V. by 16.6% in the second quarter, acquiring an additional 9,544 shares, making their total 66,901 shares valued at approximately $3.2 million.
• Several other institutional investors, including Truist Financial Corp and Signaturefd LLC, also adjusted their positions, contributing to the fact that 70% of QIAGEN's shares are now owned by institutional investors.
• QIAGEN reported earnings of $0.60 per share for the latest quarter, meeting expectations, and achieved a revenue increase of 7.7% year-over-year, amounting to $533.54 million.

US Bancorp DE increased its stake in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 16.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 66,901 shares of the company's stock after buying an additional 9,544 shares during the quarter. US Bancorp DE's holdings in QIAGEN were worth $3,215,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Exchange Traded Concepts LLC increased its position in QIAGEN by 2.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after purchasing an additional 395 shares during the period. Truist Financial Corp lifted its holdings in shares of QIAGEN by 7.7% in the 2nd quarter. Truist Financial Corp now owns 6,170 shares of the company's stock valued at $297,000 after buying an additional 439 shares during the period. SVB Wealth LLC acquired a new stake in shares of QIAGEN in the 1st quarter valued at approximately $31,000. Signaturefd LLC lifted its holdings in shares of QIAGEN by 23.2% in the 2nd quarter. Signaturefd LLC now owns 4,132 shares of the company's stock valued at $199,000 after buying an additional 778 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in shares of QIAGEN by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock valued at $51,000 after buying an additional 849 shares during the period. Hedge funds and other institutional investors own 70.00% of the company's stock.

QIAGEN Trading Up 0.6%

Shares of QIAGEN stock opened at $47.49 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The company has a market capitalization of $10.56 billion, a P/E ratio of 28.06, a P/E/G ratio of 2.48 and a beta of 0.66. The business has a 50 day moving average price of $47.00 and a 200 day moving average price of $45.65.

QIAGEN (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same period in the previous year, the firm posted $0.55 EPS. The company's quarterly revenue was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts anticipate that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Barclays set a $53.00 price target on QIAGEN and gave the company an "overweight" rating in a report on Thursday, October 2nd. UBS Group raised their price target on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Weiss Ratings reissued a "hold (c+)" rating on shares of QIAGEN in a report on Wednesday, October 8th. Bank of America raised their price target on QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. Finally, Wall Street Zen lowered QIAGEN from a "buy" rating to a "hold" rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, QIAGEN presently has a consensus rating of "Hold" and an average target price of $49.40.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.